Device therapy to modulate the autonomic nervous system to treat heart failure

Current Cardiology Reports

Volumn 14, Issue 5, 2012, Pages 593-600

  Lopshire, John C ^a   Zipes, Douglas P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autonomic nervous system; Baroreflex stimulation; Catecholamines; Device therapy; Heart failure; Neuromodulation; Parasympathetic nervous system; Reverse remodeling; Spinal cord stimulation; Sudden cardiac arrest; Sympatheticnervous system; Vagal nerve stimulation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DOXAZOSIN; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; MOXONIDINE; PRAZOSIN; PYRIDOSTIGMINE; RAMIPRIL;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BAROREFLEX STIMULATION; DEVICE THERAPY; DRUG WITHDRAWAL; ELECTRODE; ELECTROSTIMULATION THERAPY; ENDOCARDIAL SENSING ELECTRODE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; NEUROMODULATION; NONHUMAN; OXYGEN SATURATION; PRESSORECEPTOR REFLEX; RISK BENEFIT ANALYSIS; SPINAL CORD STIMULATION; SYMPATHECTOMY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; THORACOSCOPY; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; ELECTRIC STIMULATION THERAPY; HEART; HEART FAILURE; HUMANS; SPINAL CORD STIMULATION; SYMPATHECTOMY; VAGUS NERVE STIMULATION;

EID: 84870586959     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0292-8     Document Type: Article

References (64)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e1-170.
2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
3. Pepper GS, Lee RW. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med. 1999;159:225-34. (Pubitemid 29075642)
4. Regitz V, Leuchs B, Bossaller C, et al. Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur Heart J. 1991;12(Suppl):S171-4.
5. Piacentino III V, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003;92:651-8. (Pubitemid 36417700)
6. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-41.
7. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-34. (Pubitemid 28443398)
8. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol. 2006;33:1269-74. (Pubitemid 44923921)
9. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769-77.
10. Fishman GI, Chugh SS, DiMarco J, et al. Sudden cardiac death prediction and prevention: report from a national heart, lung, and blood institute and heart rhythm society workshop. Circulation. 2010;122:2335-48.
11. Newton GE, Parker AB, Landzberg JS, et al. Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. J Clin Invest. 1996;98:2756-63. (Pubitemid 26427402)
12. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823-30. (Pubitemid 47277500)
13. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol. 1995;268:R317-23.
14. Damy T, Ratajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived no production in the failing human heart. Lancet. 2004;363:1365-7. (Pubitemid 38529877)
15. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117:289-96. (Pubitemid 46203953)
16. Dargie HJ, Lechat P. The cardiac insufficiency bisoprolol study (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13. (Pubitemid 29037695)
17. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7.
18. Eichorn E, Domanski M, Krause-Steinrauf H, Anderson J, Boardman K, Bristow M. The beta-blocker evaluation of survival trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.
19. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55. (Pubitemid 26152713)
20. PackerM, CoatsAJ, FowlerMB, et al. Effect on carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8. (Pubitemid 32479962)
21. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. results of a Veterans Administration cooperative study. N Engl J Med. 1986;314:1547-52. (Pubitemid 16114684)
22. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-75.
23. Giles TD, Thomas MG, Quiroz A, et al. Acute and short-term effects of clonidine in heart failure. Angiology. 1987;38:537-48. (Pubitemid 17134416)
24. Issa ZF, Ujhelyi MR, Hildebrand KR, et al. Intrathecal clonidine reduces the incidence of ischemia-provoked ventricular arrhythmias in a canine post infarction heart failure model. Heart Rhythm. 2005;2:1122-7. (Pubitemid 41472164)
25. Cohn JN, Pfeffer MA, Rouleau J, et al. on behalf of the MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-67. (Pubitemid 38043972)
26. Mahajan A, Moore J, Cesario DA. Use of thoracic epidural anesthesia for management of electrical storm: a case report. Heart Rhythm. 2005;2:1359-62. (Pubitemid 43055420)
27. Zipes DP, Festoff B, Schaal SF, et al. Treatment of ventricular arrhythmia by permanent atrial pacemaker and cardiac sympathectomy. Ann Intern Med. 1968;68:591-7.
28. Wilde AA, Bhuiyan A, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024-9. (Pubitemid 351656456)
29. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using videoassisted thoracic surgery. Heart Rhythm. 2009;6:752-9.
30. Behling A, Moraes RS, Rohde LE, et al. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmias and enhances heart rate variability in heart failure. Am Heart J. 2003;146:494-500. (Pubitemid 37083085)
31. Binkley PF, Haas GS, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol. 1993;21:655-61. (Pubitemid 23076283)
32. Foreman R, Linderoth B, Ardelt J, et al. Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris. Cardiovasc Res. 2000;47:367-75. (Pubitemid 30625299)
33. Southerland EM, Milhorn DM, Foreman RD, et al. Preemptive, but not reactive, spinal cord stimulation mitigates transient ischemiainduced myocardial infarction via cardiac adrenergic neurons. Am J Physiol Heart Circ Physiol. 2007;292:H311-7. (Pubitemid 46105192)
34. JE Olgin, Takahashi T, Wilson E, et al. Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol. 2002;13:475-81. (Pubitemid 34494268)
35. Issa ZF, Zhou X, Ujhelyi MR, et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a post-infarction heart failure canine model. Circulation. 2005;111:3217-20. (Pubitemid 40874992)
36. Odenstedt J, Linderoth B, Bergfeldt L, et al. Spinal cord stimulation effects on myocardial ischemia, infarct size, ventricular arrhythmia, and noninvasive electrophysiology in a porcine ischemia-reperfusion model. Heart Rhythm. 2011;8:892-8.
37. Lopshire JC, Zhou X, Dusa C, et al. Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation. 2009;120:286-94.
38. Lopshire JC, Zhou X, Mullen T, et al. The site and intensity of spinal cord stimulation determines remodeling response in canine heart failure. Hear Rhythm. 2011;8:S78.
39. Liu Y, Yue WS, Liao SY, et al. Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. J Cardiovasc Electrophysiol. 2012;23(5):534-540.
40. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res. 1991;68:1471-81.
41. Li M, Zheng C, Sato T, Kawada T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004;109:120-4. (Pubitemid 38056032)
42. Zheng C, Li M, Inagaki M, Kawada T, et al. Vagal stimulation markedly suppresses arrhythmias in conscious rats with chronic heart failure after myocardial infarction. Conf Proc IEEE Eng Med Biol Soc. 2004;7:7072-5.
43. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circulation. 2009;2:692-9.
44. Sabbah HN, Ilsar I, Zaretsky A, et al. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev. 2011;16:171-8.
45. Filippone JD, Bisognano JD. Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2007;16:403-8. (Pubitemid 47254689)
46. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-26.
47. Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail. 2011;4(1):65-70.
48. Determining the feasibility of spinal cord neuromodulation for the treatment of chronic heart failure (defeat-HF). Available at: http://clinicaltrials. gov/ct2/show/NCT01112579.
49. Cornelussen RN, Splett V, Klepfer RN, et al. Electrical modalities beyond pacing for the treatment of heart failure. Heart Fail Rev. 2011;16:315-25.
50. Spinal cord stimulation for heart failure (SCS HEART). Available at: http://clinicaltrials. gov/ct2/show/NCT01362725. Accessed 1 Apr 2012.
51. Neurostimulation of spinal nerves that affect the heart. Available at: http://clinicaltrials. gov/ct2/show/NCT01124136. Accessed 1 Apr 2012.
52. De Ferrari GM, Ezra OB, Ajmone-Marsan N, et al. Chronic vagal stimulation in patients with heart failure is feasible, safe and appears beneficial. Eur Heart J. 2006;27:330-7.
53. Schwartz PJ, Gaetano M, De Ferrari GM. Vagal stimulation for heart failure: Background and first in-man study. Heart Rhythm. 2009;6(11):S76-81.
54. CardioFit™ for the treatment of heart failure. Available at: http://clinicaltrials. gov/ct2/show/NCT00461019. Accessed 1 Apr 2012.
55. De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation; a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32(7):847-55.
56. Increase of vagal tone in chf (inovate-hf). Available at: http://clinicaltrials. gov/ct2/show/NCT01303718. Accessed 1 Apr 2012.
57. Neural cardiac therapy for heart failure study (NECTAR-HF). Available at: http://clinicaltrials. gov/ct2/show/NCT01385176. Accessed 1 Apr 2012.
58. Rheos® diastolic heart failure trial. Available at: http://clinicaltrials. gov/ct2/show/NCT00718939. Accessed 1 Apr 2012.
59. Lovett EG, Schafer J, Kaufman CL. Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. Proceedings of the Engineering in Medicine and Biology Society, 2009 Annual International Conference of the IEEE, pp 4626-30.
60. Baroreflex activation therapy in heart failure. Available at: http://clinicaltrials. gov/ct2/show/NCT01484288. Accessed 1 Apr 2012.
61. Georgakopoulos D, Little WC, Abraham WT, et al. Chronic baroreflex activation: a potential therapeutic approach to treat heart failure with preserved ejection fraction. J Card Fail. 2011;17:167-78.
62. Rheos HOPE4HF trial. Available at: http://clinicaltrials. gov/ct2/show/NCT00957073. Accessed 1 Apr 2012.
63. Barostim neo system in the treatment of heart failure. Available at: http://clinicaltrials. gov/ct2/show/NCT01471860. Accessed 1 Apr 2012.
64. Lopshire JC, Zhou X, Dusa C, et al. Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation. 2009;120:286-94.